Research programme: chimeric antigen receptor T cell therapeutics - City of Hope National Medical Center/Mustang Bio

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - City of Hope National Medical Center/Mustang Bio

Alternative Names: CAR-T cells - Coronado/City of Hope; CAR-T cells - Mustang Bio; HER2-BBζ CAR-T cells; MB 103; MB 104; MB 105; MB-103 HER2 CAR; MB-104 CS1 CAR; MB-105 PSCA CAR

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Mustang Bio
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 May 2018 Mustang Bio plans to file an IND application for Cancer in 2018
  • 14 May 2018 Mustang Bio plans a clinical trial for CAR T programme in 2018
  • 31 Oct 2017 Mustang Bio plans a first-in-human phase I trial for in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top